These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 29035392

  • 1. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide.
    Fouzia NA, Edison ES, Lakshmi KM, Korula A, Velayudhan SR, Balasubramanian P, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A.
    Bone Marrow Transplant; 2018 Feb; 53(2):169-174. PubMed ID: 29035392
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I, Rowe JM, Khalil A, Ben-Arush M, Elhasid R.
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [Abstract] [Full Text] [Related]

  • 3. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
    Fu L, Wei N, Wang JS, Wu L, Wang YN, Huang DY, Liu JL, Wang Z.
    Zhonghua Nei Ke Za Zhi; 2017 Apr 01; 56(4):273-278. PubMed ID: 28355720
    [Abstract] [Full Text] [Related]

  • 4. The study of engraftment after hematopoietic stem cell transplantation: From the presence of mixed chimerism to the development of immunological tolerance.
    Andreani M, Gregori S.
    HLA; 2018 Dec 01; 92 Suppl 2():57-59. PubMed ID: 30270557
    [Abstract] [Full Text] [Related]

  • 5. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
    Karasu GT, Yesilipek MA, Karauzum SB, Uygun V, Manguoglu E, Kupesiz A, Hazar V.
    Pediatr Blood Cancer; 2012 Mar 01; 58(3):453-8. PubMed ID: 21990066
    [Abstract] [Full Text] [Related]

  • 6. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Carrabba MG, Bellio L, Milani R, Lorentino F, Stanghellini MT, De Freitas T, Marktel S, Bernardi M, Corti C, Vago L, Bonini C, Ciceri F, Peccatori J.
    Biol Blood Marrow Transplant; 2015 Aug 01; 21(8):1506-14. PubMed ID: 26001696
    [Abstract] [Full Text] [Related]

  • 7. G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.
    Li Q, Luo J, Zhang Z, Liu L, Luo L, Yang G, Liu R, Shi L, Huang R, Wu M, Lai Y.
    Biol Blood Marrow Transplant; 2019 Oct 01; 25(10):2040-2044. PubMed ID: 31207293
    [Abstract] [Full Text] [Related]

  • 8. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
    Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, Takahashi N, Tajima K, Kim SW, Mori SI, Tanosaki R, Takaue Y, Heike Y.
    Biol Blood Marrow Transplant; 2008 Oct 01; 14(10):1148-1155. PubMed ID: 18804045
    [Abstract] [Full Text] [Related]

  • 9. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
    Chan WYK, Kwok JSY, Chiang AKS, Chan GCF, Lee PPW, Ha SY, Cheuk DKL.
    Pediatr Transplant; 2021 Aug 01; 25(5):e13945. PubMed ID: 33314508
    [Abstract] [Full Text] [Related]

  • 10. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients.
    Chen H, Li XY, Zhan LP, Fang JP, Huang K, Li Y, Weng WJ, Xu LH, Xu HG, Zhou DH.
    Pediatr Transplant; 2020 Dec 01; 24(8):e13876. PubMed ID: 33098346
    [Abstract] [Full Text] [Related]

  • 11. The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia.
    Choeyprasert W, Pakakasama S, Anurathapan U, Songdej D, Sirachainun N, Sirireung S, Panthangkool W, Hongeng S.
    Pediatr Transplant; 2012 Sep 01; 16(6):E238-40. PubMed ID: 21895905
    [Abstract] [Full Text] [Related]

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
    Faraci M, Bagnasco F, Leoni M, Giardino S, Terranova P, Subissi L, Di Duca M, Di Martino D, Lanino E.
    Biol Blood Marrow Transplant; 2018 May 01; 24(5):1088-1093. PubMed ID: 29292059
    [Abstract] [Full Text] [Related]

  • 14. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.
    Biol Blood Marrow Transplant; 2013 Mar 01; 19(3):492-5. PubMed ID: 23160007
    [Abstract] [Full Text] [Related]

  • 15. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
    Pichler H, Fritsch G, König M, Daxberger H, Glogova E, Pötschger U, Breuer S, Lawitschka A, Güclü ED, Karlhuber S, Holter W, Haas OA, Lion T, Matthes-Martin S.
    Br J Haematol; 2016 Jun 01; 173(6):905-17. PubMed ID: 26996395
    [Abstract] [Full Text] [Related]

  • 16. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
    Alimoghaddam K, Ghaffari H, Foroughi F, Chardouli B, Sanaat Z, Bahar B, Mousavi A, Iravani M, Ghavamzadeh A.
    Arch Iran Med; 2006 Apr 01; 9(2):99-103. PubMed ID: 16649348
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
    Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.
    Biol Blood Marrow Transplant; 2015 Feb 01; 21(2):288-92. PubMed ID: 25464116
    [Abstract] [Full Text] [Related]

  • 18. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
    Korula A, Pn N, Devasia A, Lakshmi KM, Abraham A, Sindhuvi E, George B, Srivastava A, Mathews V.
    Biol Blood Marrow Transplant; 2018 Jan 01; 24(1):103-108. PubMed ID: 29032269
    [Abstract] [Full Text] [Related]

  • 19. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 20. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
    Horn B, Petrovic A, Wahlstrom J, Dvorak CC, Kong D, Hwang J, Expose-Spencer J, Gates M, Cowan MJ.
    Biol Blood Marrow Transplant; 2015 Apr 20; 21(4):729-37. PubMed ID: 25644958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.